Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct 7;9(10):1676-83.
doi: 10.2215/CJN.10441013. Epub 2014 Aug 7.

Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial

Ellen K Hoogeveen  1 , Johanna M Geleijnse  2 , Daan Kromhout  2 , Theo Stijnen  3 , Eugenie F Gemen  4 , Ron Kusters  4 , Erik J Giltay  5
Affiliations
Randomized Controlled Trial

Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial

Ellen K Hoogeveen et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: Kidney function gradually decreases with age, and myocardial infarction accelerates this deterioration. Omega-3 (n-3) fatty acids may slow down the decline of kidney function. The effect of marine and plant-derived n-3 fatty acids on kidney function in patients after myocardial infarction was examined.

Design, setting, participants, & measurements: In the Alpha Omega Trial, 2344 patients with history of myocardial infarction ages 60-80 years old (81% men) were randomized to one of four trial margarines. The patients received an additional targeted amount of 400 mg/d eicosapentaenoic acid and docosahexaenoic acid, 2 g/d α-linolenic acid, eicosapentaenoic acid-docosahexaenoic acid plus α-linolenic acid, or placebo for 40 months. Serum cystatin C and serum creatinine were assessed at baseline and after 40 months. Creatinine-cystatin C-based GFR was estimated with the Chronic Kidney Disease Epidemiology Collaboration equation.

Results: Patients consumed 19.9 g margarine/d, providing an additional 239 mg/d eicosapentaenoic acid with 159 mg/d docosahexaenoic acid, 1.99 g/d α-linolenic acid, or both in the active treatment groups. After 40 months, compared with baseline, mean (±SD) creatinine-cystatin C-based GFR was -6.9 (±12.6), -4.8 (±13.4), -6.2 (±12.8), and -6.0 (±13.0) ml/min per 1.73 m(2) in the placebo, eicosapentaenoic acid-docosahexaenoic acid, α-linolenic acid, and eicosapentaenoic acid-docosahexaenoic acid plus α-linolenic acid groups, respectively. After 40 months, in patients receiving eicosapentaenoic acid-docosahexaenoic acid compared with placebo, the decline in creatinine-cystatin C-based GFR was 2.1 less (95% confidence interval, 0.6 to 3.6; P<0.01) ml/min per 1.73 m(2); other comparisons were not statistical significant. Odds ratios (95% confidence intervals) of incident CKD (<60 ml/min per 1.73 m(2)) and rapid decline of kidney function (≥3 ml/min per year) for eicosapentaenoic acid-docosahexaenoic acid compared with placebo were 0.83 (0.58 to 1.18) and 0.85 (0.67 to 1.08), respectively.

Conclusions: Long-term supplementation with 400 mg/d eicosapentaenoic acid-docosahexaenoic acid provides a small beneficial effect on kidney function in patients with a history of myocardial infarction.

Trial registration: ClinicalTrials.gov NCT00127452.

Keywords: CKD; cardiovascular disease; clinical trial; nutrition; omega-3 fatty acids.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of the 2344 patients in the Alpha Omega Trial: randomization and follow-up. ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.
Figure 2.
Figure 2.
Effect of intervention of n-3 fatty acids on yearly decline in creatinine–cystatin C-based kidney function in 2344 patients of the Alpha Omega Trial according to treatment group. Yearly mean changes of eGFRcr-cysC compared with baseline with 95% confidence intervals. P values were obtained by means of the t test for independent samples using the placebo group as the reference. eGFRcr-cysC, creatinine–cystatin C-based eGFR; n-3, Omega-3.
See this image and copyright information in PMC

References

    1. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M: Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int 72: 632–637, 2007 - PubMed
    1. Kronborg J, Solbu M, Njølstad I, Toft I, Eriksen BO, Jenssen T: Predictors of change in estimated GFR: A population-based 7-year follow-up from the Tromso study. Nephrol Dial Transplant 23: 2818–2826, 2008 - PubMed
    1. Hoogeveen EK, Halbesma N, Rothman KJ, Stijnen T, van Dijk S, Dekker FW, Boeschoten EW, de Mutsert R, Netherlands Cooperative Study on the Adequacy of Dialysis-2 (NECOSAD) Study Group : Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 7: 280–288, 2012 - PMC - PubMed
    1. Eijkelkamp WB, de Graeff PA, van Veldhuisen DJ, van Dokkum RP, Gansevoort RT, de Jong PE, de Zeeuw D, Hillege HL, Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study Group : Effect of first myocardial ischemic event on renal function. Am J Cardiol 100: 7–12, 2007 - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004 - PubMed

Publication types

MeSH terms

Associated data